Aratana Therapeutics, Inc. (PETX) Receives Consensus Recommendation of “Buy” from Analysts
Aratana Therapeutics, Inc. (NASDAQ:PETX) has received an average rating of “Buy” from the eight analysts that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $10.40.
A number of equities analysts recently commented on PETX shares. Jefferies Group LLC set a $11.00 price target on shares of Aratana Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 14th. Zacks Investment Research raised shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 1st. ValuEngine lowered shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 31st. Finally, Stifel Nicolaus decreased their target price on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, May 10th.
In other Aratana Therapeutics news, insider Peter Steven St sold 50,000 shares of the firm’s stock in a transaction dated Monday, April 17th. The shares were sold at an average price of $5.54, for a total value of $277,000.00. Following the transaction, the insider now directly owns 582,693 shares of the company’s stock, valued at approximately $3,228,119.22. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 6.70% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Financial Counselors Inc. purchased a new position in Aratana Therapeutics during the first quarter valued at approximately $101,000. American International Group Inc. raised its position in Aratana Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 20,534 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,354 shares in the last quarter. Ray Gerald L & Associates Ltd. raised its position in Aratana Therapeutics by 38.2% in the first quarter. Ray Gerald L & Associates Ltd. now owns 23,900 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 6,600 shares in the last quarter. A.R.T. Advisors LLC raised its position in Aratana Therapeutics by 19.3% in the fourth quarter. A.R.T. Advisors LLC now owns 17,900 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 2,900 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY raised its position in Aratana Therapeutics by 17.9% in the first quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 3,883 shares in the last quarter. 67.91% of the stock is currently owned by hedge funds and other institutional investors.
Aratana Therapeutics (NASDAQ:PETX) traded up 7.47% during mid-day trading on Monday, reaching $6.91. 273,595 shares of the company were exchanged. The stock’s market capitalization is $262.28 million. Aratana Therapeutics has a 12-month low of $4.97 and a 12-month high of $10.73. The company’s 50 day moving average price is $6.14 and its 200-day moving average price is $6.58.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.34) EPS for the quarter, hitting analysts’ consensus estimates of ($0.34). Aratana Therapeutics had a negative net margin of 66.72% and a negative return on equity of 14.95%. The business had revenue of $3.80 million for the quarter, compared to analyst estimates of $3.05 million. During the same period last year, the firm earned ($0.52) earnings per share. Aratana Therapeutics’s revenue for the quarter was up 2135.3% compared to the same quarter last year. On average, equities research analysts forecast that Aratana Therapeutics will post ($1.08) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/06/19/aratana-therapeutics-inc-petx-receives-consensus-recommendation-of-buy-from-analysts.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.